Plasma Protein Therapeutics Market by Product, Application

Description

List of Tables

The Plasma Protein Therapeutics Market was valued at USD 32.55 billion in 2023, expected to reach USD 36.19 billion in 2024, and is projected to grow at a CAGR of 11.37%, to USD 69.18 billion by 2030.

Plasma Protein Therapeutics involves treatments derived from human plasma proteins for diseases such as hemophilia, immune deficiencies, and rare disorders. The scope encompasses therapies like immunoglobulins, albumin, and clotting factors designed for critical patient needs. The necessity lies in the unique therapeutic benefits these proteins offer, often essential for patients who lack alternatives. Applications extend from treatment and management of clotting disorders and immune system deficiencies to critical care in emergency medicine. End-use is primarily in hospitals, specialized clinics, and research institutions, where there is a dire need for effective therapies. The market is driven by factors like increasing prevalence of rare diseases, technological advancements in plasma fractionation, and rising healthcare expenditure. Latest opportunities arise from the surge in demand for immunoglobulins and innovations in recombinant therapies, coupled with market expansion in emerging regions due to improving healthcare infrastructure. To capitalize on these opportunities, businesses should focus on strategic partnerships, and regional expansions. However, market growth is currently challenged by constraints such as the high cost of therapies, stringent regulatory frameworks, and the ethical issues surrounding plasma donation. Additionally, complexities in product manufacturing and limited plasma supply pose significant hurdles. The best areas for innovation include developing new plasma-derived therapies, enhancing plasma collection efficiency, and exploring genetic engineering to improve recombinant alternatives. The market is primarily characterized by intense competition, where strategic mergers, acquisitions, and collaborations are common in fostering growth. Businesses should prioritize investment in research for novel therapies and potential synthetic alternatives to boost supply. Overall, the market is poised for growth, driven by innovations and expanding access, but must navigate the challenges of cost, regulation, and supply chain complexities.

KEY MARKET STATISTICS
Base Year [2023]	USD 32.55 billion
Estimated Year [2024]	USD 36.19 billion
Forecast Year [2030]	USD 69.18 billion
CAGR (%)	11.37%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Plasma Protein Therapeutics Market

The Plasma Protein Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increased Prevalence of Autoimmune and Neurological Diseases
- Need for Regular Infusions or Injections Throughout the Life of the Patient
- Surging Access and Affordability of Plasma Protein Therapies for Patients
Market Restraints
- Adverse Effects of Plasma Protein Therapeutics
Market Opportunities
- Increasing Research and Development Activity Related to the Plasma Protein
- Development of Efficient Protein Plasma Extraction/Manufacturing Process
Market Challenges
- Strict Regulations Pertaining to Handling of Plasma Protein

Porter's Five Forces: A Strategic Tool for Navigating the Plasma Protein Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Plasma Protein Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Plasma Protein Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Plasma Protein Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Plasma Protein Therapeutics Market

A detailed market share analysis in the Plasma Protein Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Plasma Protein Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Plasma Protein Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Plasma Protein Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Bio Products Laboratory Ltd., CSL Limited, Takeda Pharmaceutical Company Limited, DiaPharma, GC Biopharma corp, AmerisourceBergen Corporation, Laboratory Corporation of America Holdings, Bruker Corporation, Octapharma AG, KalVista Pharmaceuticals, Emergent BioSolutions, FFF Enterprises, Inc., Plasma Technologies, LLC, LFB SA, Kamada Ltd., PlasmaGen BioSciences Pvt. Ltd., Reliance Industries Limited, Thermo Fisher Scientific, Inc., Grifols, S.A., China Biologic Products Holdings, Inc., Hemarus Therapeutics Limited, Access Biologicals LLC, ADMA Biologics, Inc., Baxter International Inc., and Kedrion S.p.A..

Market Segmentation & Coverage

This research report categorizes the Plasma Protein Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across Albumins, C1-esterase Inhibitors, Coagulation Factors, Hyperimmune Globulins, and Immunoglobulins.
Based on Application, market is studied across Hereditary Angioedema, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, and Secondary Immunodeficiency.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-030EE4851670

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increased Prevalence of Autoimmune and Neurological Diseases
  - 5.1.1.2. Need for Regular Infusions or Injections Throughout the Life of the Patient
  - 5.1.1.3. Surging Access and Affordability of Plasma Protein Therapies for Patients
- 5.1.2. Restraints
  - 5.1.2.1. Adverse Effects of Plasma Protein Therapeutics
- 5.1.3. Opportunities
  - 5.1.3.1. Increasing Research and Development Activity Related to the Plasma Protein
  - 5.1.3.2. Development of Efficient Protein Plasma Extraction/Manufacturing Process
- 5.1.4. Challenges
  - 5.1.4.1. Strict Regulations Pertaining to Handling of Plasma Protein
5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising usage of C1-esterase inhibitors to control and prevent the swelling attacks associated with HAE
- 5.2.2. Application: Growing application of plasma protein therapeutics in the secondary immunodeficiency due to prevalence of cancer and autoimmune diseases
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
5.5. Client Customization

6. Plasma Protein Therapeutics Market, by Product

6.1. Introduction
6.2. Albumins
6.3. C1-esterase Inhibitors
6.4. Coagulation Factors
6.5. Hyperimmune Globulins
6.6. Immunoglobulins

7. Plasma Protein Therapeutics Market, by Application

7.1. Introduction
7.2. Hereditary Angioedema
7.3. Idiopathic Thrombocytopenic Purpura
7.4. Primary Immunodeficiency Disorder
7.5. Secondary Immunodeficiency

8. Americas Plasma Protein Therapeutics Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Plasma Protein Therapeutics Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Plasma Protein Therapeutics Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
- 11.3.1. GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia
- 11.3.2. PlasmaGen Biosciences Opens New, State-of-the-Art Manufacturing Facility for Blood Plasma Products in Kolar, Bengaluru
- 11.3.3. Takeda to build USD 770 million plasma-derived therapy plant in Japan

Companies Mentioned

1. Bio Products Laboratory Ltd.
2. CSL Limited
3. Takeda Pharmaceutical Company Limited
4. DiaPharma
5. GC Biopharma corp
6. AmerisourceBergen Corporation
7. Laboratory Corporation of America Holdings
8. Bruker Corporation
9. Octapharma AG
10. KalVista Pharmaceuticals
11. Emergent BioSolutions
12. FFF Enterprises, Inc.
13. Plasma Technologies, LLC
14. LFB SA
15. Kamada Ltd.
16. PlasmaGen BioSciences Pvt. Ltd.
17. Reliance Industries Limited
18. Thermo Fisher Scientific, Inc.
19. Grifols, S.A.
20. China Biologic Products Holdings, Inc.
21. Hemarus Therapeutics Limited
22. Access Biologicals LLC
23. ADMA Biologics, Inc.
24. Baxter International Inc.
25. Kedrion S.p.A.